Literature DB >> 17625516

New programs for gene- and cell-based therapies at NHLBI.

S I Skarlatos1.   

Abstract

The development of new and novel clinical therapies depends on our ability to translate basic research findings into meaningful clinical applications. These "translational studies" are expensive and complex but necessary if we are to develop new treatments that prevent or treat heart, lung, and blood diseases. This study describes newly created programs at NHLBI (National Heart, Lung, and Blood Institute), which support academic research efforts to translate gene- and cell-based therapies into viable clinical applications.

Entities:  

Mesh:

Year:  2007        PMID: 17625516     DOI: 10.1038/sj.clpt.6100289

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Clinical and translational sciences: at the intersection of molecular and individualized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

Review 2.  Dr. Sonia Skarlatos and the National Heart, Lung, and Blood institute translational research and resource programs.

Authors:  Cheryl L McDonald
Journal:  Hum Gene Ther       Date:  2013-11       Impact factor: 5.695

Review 3.  DNAzymes and cardiovascular disease.

Authors:  V L Benson; L M Khachigian; H C Lowe
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

4.  Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN).

Authors:  Robert D Simari; Lemuel A Moyé; Sonia I Skarlatos; Stephen G Ellis; David X M Zhao; James T Willerson; Timothy D Henry; Carl J Pepine
Journal:  J Cardiovasc Transl Res       Date:  2010-02       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.